European and Italian regulation on orphan medicinal products | Zendy

Roberta Joppi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

European and Italian regulation on orphan medicinal products

Author(s) -

Roberta Joppi

Publication year - 2013

Publication title -

farmeconomia health economics and therapeutic pathways

Language(s) - English

Resource type - Journals

eISSN - 1721-6923

pISSN - 1721-6915

DOI - 10.7175/fe.v14i2.633

Subject(s) - orphan drug , marketing authorization , authorization , incentive , legislation , european union , business , agency (philosophy) , rare disease , member states , medicine , disease , political science , international trade , law , economics , bioinformatics , biology , philosophy , computer security , epistemology , pathology , computer science , microeconomics

The paper presents an overview of the European and Italian Regulation on Orphan Medicinal Products (OMPs), along with some data on the OMPs licensed in the EU from 2000 to 2012. The EU legislation encourages pharmaceutical companies to develop drugs for rare diseases, so-called “orphan drugs”. The European Medicine Agency recognizes orphan drug status mainly on the basis of the prevalence of the disease (≤ 5/10,000), and potential benefit. Orphan status implies incentives for pharmaceutical companies. From 2000 up to 2012 890 candidate orphan drug designations received a positive opinion and the marketing authorization was granted to 72 OMPs corresponding to 80 different indications. Currently, 59 OMPs are available to Italian patients either because licensed to the market by the AIFA or included in the list of the L. 648/96. Despite of an encouraging regulation nearly all the currently estimated rare diseases still await treatments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research